SiBone $SIBN Shares Purchased by Royce & Associates LP

Royce & Associates LP increased its holdings in shares of SiBone (NASDAQ:SIBN) by 47.3% during the 3rd quarter, Holdings Channel reports. The institutional investor owned 162,051 shares of the company’s stock after purchasing an additional 52,019 shares during the period. Royce & Associates LP’s holdings in SiBone were worth $2,385,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. American Century Companies Inc. boosted its holdings in SiBone by 22.5% in the third quarter. American Century Companies Inc. now owns 2,838,107 shares of the company’s stock worth $41,777,000 after acquiring an additional 521,683 shares in the last quarter. Vanguard Group Inc. raised its position in shares of SiBone by 1.7% in the 3rd quarter. Vanguard Group Inc. now owns 2,489,989 shares of the company’s stock valued at $36,653,000 after purchasing an additional 41,449 shares during the last quarter. First Light Asset Management LLC boosted its stake in SiBone by 8.6% in the 2nd quarter. First Light Asset Management LLC now owns 1,751,001 shares of the company’s stock worth $32,954,000 after purchasing an additional 138,593 shares in the last quarter. Impax Asset Management Group plc grew its position in SiBone by 48.2% during the 3rd quarter. Impax Asset Management Group plc now owns 1,025,010 shares of the company’s stock worth $15,088,000 after purchasing an additional 333,249 shares during the last quarter. Finally, Marshall Wace LLP grew its position in SiBone by 18.2% during the 2nd quarter. Marshall Wace LLP now owns 436,213 shares of the company’s stock worth $8,210,000 after purchasing an additional 67,202 shares during the last quarter. 98.11% of the stock is currently owned by hedge funds and other institutional investors.

SiBone Trading Down 4.4%

NASDAQ SIBN opened at $14.07 on Friday. SiBone has a 1 year low of $12.49 and a 1 year high of $21.89. The company has a debt-to-equity ratio of 0.20, a current ratio of 8.55 and a quick ratio of 7.21. The company has a market capitalization of $621.47 million, a PE ratio of -31.98 and a beta of 0.69. The company has a fifty day moving average of $17.01 and a 200 day moving average of $16.81.

SiBone (NASDAQ:SIBN) last released its quarterly earnings data on Monday, February 23rd. The company reported ($0.04) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.13) by $0.09. The business had revenue of $56.35 million during the quarter, compared to analyst estimates of $56.26 million. SiBone had a negative return on equity of 11.01% and a negative net margin of 9.41%. Research analysts forecast that SiBone will post -0.78 earnings per share for the current year.

Insider Buying and Selling at SiBone

In other news, insider Anthony J. Recupero sold 21,049 shares of the firm’s stock in a transaction dated Tuesday, February 17th. The stock was sold at an average price of $15.40, for a total transaction of $324,154.60. Following the sale, the insider directly owned 243,418 shares in the company, valued at $3,748,637.20. This trade represents a 7.96% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Michael A. Pisetsky sold 20,756 shares of SiBone stock in a transaction dated Tuesday, February 17th. The shares were sold at an average price of $15.35, for a total value of $318,604.60. Following the completion of the transaction, the senior vice president owned 285,974 shares of the company’s stock, valued at approximately $4,389,700.90. This represents a 6.77% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders have sold 247,653 shares of company stock worth $4,234,702. 4.00% of the stock is currently owned by insiders.

Analyst Ratings Changes

A number of research firms have issued reports on SIBN. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of SiBone in a report on Monday, December 29th. Needham & Company LLC upped their target price on SiBone from $24.00 to $27.00 and gave the company a “buy” rating in a research report on Tuesday, December 16th. Morgan Stanley lifted their price target on SiBone from $20.00 to $23.00 and gave the stock an “overweight” rating in a research report on Tuesday, December 2nd. Canaccord Genuity Group boosted their price target on SiBone from $26.00 to $27.00 and gave the company a “buy” rating in a research note on Wednesday, December 17th. Finally, Truist Financial restated a “buy” rating and issued a $24.00 price objective (up from $23.00) on shares of SiBone in a research note on Tuesday, February 24th. Six research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $24.67.

SiBone Company Profile

Si-BONE, Inc is a commercial‐stage medical device company focused on the design, development and commercialization of implant systems to treat degenerative conditions of the sacroiliac (SI) joint. Its flagship product, the iFuse Implant System, consists of triangular titanium implants that are inserted via a minimally invasive surgical procedure to stabilize the SI joint and alleviate chronic lower back and buttock pain.

FDA‐cleared in 2012, the iFuse portfolio has expanded to include the iFuse-3D and iFuse-3Di devices, which feature a porous, 3D-printed surface to promote bone ongrowth and biological fixation.